Personalized

Regulatory Innovation for a More Personalized Era of Medicine

Pharma's Almanac

CRO Partnerships

Building Resilient Development Models: How Mid-Size Pharma Can Scale Without Losing Control

Brian Healey

IQVIA

Expedited Pathways

Accelerated Pathways: Are They Delivering on Their Promise?

David Alvaro, Ph.D.

Pharma's Almanac

Clinical Evidence

Rethinking Clinical Evidence Requirements in Rare Diseases

David Alvaro, Ph.D.

Pharma's Almanac

Protein Misfolding

Protein Misfolding as a Therapeutic Axis in Neurodegenerative Disease

David Alvaro, Ph.D.

Pharma's Almanac

Cell-Free Synthesis

Cell-Free Biomanufacturing and the Future of Flexible Biologics Production

David Alvaro, Ph.D.

Pharma's Almanac

Supply Chain

Outsourcing, Fragmentation, and the New Supply Chain Resilience Challenge

Pharma's Almanac

Pathfinder

Lipid Nanoparticles vs. Viral Vectors for Gene Delivery: Which Platform Is Better?

Nice Insight

Outsourcing

The Hidden Operational Costs of Multi-Vendor Outsourcing Models

Pharma's Almanac

Digital Sampling

Enhancing Quality and Environmental Monitoring Efficiency Through Paperless Sampling

Jiwoon Kim; Neulbit Kim; Hyeonjung Park

Samsung Biologics

Alzheimer Therapies

Beyond Amyloid: Building the Next Alzheimer’s Disease Therapeutic Ecosystem

David Alvaro, Ph.D.

Pharma's Almanac

Peptides

Enabling the Commercialization of Peptide Therapeutics with Manufacturing Advances

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Protein Engineering

Exponential Advances in Protein Engineering

Cynthia A. Challener, Ph.D.

Pharma's Almanac

Molecular Barcodes

Molecular Tags, DNA Barcodes, and the Future of Pharmaceutical Supply Chain Authentication

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

Lyophilized vs. Liquid Drug Formulations: Which Formulation Strategy Is Better?

Nice Insight

AI in Manufacturing

Validating and Governing AI in GMP Manufacturing

Pharma's Almanac

AI Data Integrity

Data Integrity in the Age of AI-Assisted Manufacturing

Pharma's Almanac

BsAbs

Why Bispecific Antibody Architecture Is a CMC Decision

David Alvaro, Ph.D.

Pharma's Almanac

Continuous VV

The Stepwise Future of Continuous Viral Vector Manufacturing

David Alvaro, Ph.D.

Pharma's Almanac

Pathfinder

AAV vs. Lentiviral Vectors: Which Viral Vector Is Better for Gene Therapy?

Nice Insight